Zure produktuak, zerbitzuak edo biak beste enpresa batengandik bereizi nahi badituzu, baliteke marka edo izen komertzial bat behar izatea. Ezagutu zer diren, zer den erregistratzeko prozedura eta zer dakarren.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Arazo tekniko bat konpontzen duen edo abantaila praktiko bat duen gailu, produktu edo prozedura berri bat baduzu, hura babesteko hainbat modu daude Espainian eta beste herrialde batzuetan. Ikusi nola egin.
Zure berrikuntza zure produktuaren estetikan, apainduran edo itxuran datza? Babestu diseinu industrial baten bidez. Jakin ezazu zer eskubide ematen dituen erregistroak eta nola egin izapideak.
Mundu osoan argitaratutako patenteak informazio zientifiko, tekniko eta komertzialaren iturri baliotsua dira.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
Ekintzailea edo enpresa bazara eta zure negozioaren errentagarritasuna sustatu eta hobetu nahi baduzu, zure erakundeko aktibo ukiezinak behar bezala babestuz, gune honetan aurkituko duzu behar duzuna.
128
resultados
Última actualización
14/03/2025 [06:56:00]
Resultados 25 a 50 de 128
Resumen de: US2025064362A1
An embodiment may provide a method for calibrating sensitivity for glucose measurement including: obtaining an offset value for determining sensitivity; determining a first sensitivity from a sensor data and a reference glucose value, based on the offset value; and determining sensitivity by adjusting the first sensitivity, wherein the determining of the sensitivity includes obtaining one sensitivity, and determining sensitivity A by adjusting the one sensitivity by reflecting an average sensor data obtained by averaging a plurality of sensor data and an average glucose value obtained by averaging a plurality of glucose values to the one sensitivity; and determining the sensitivity A as the sensitivity.
Resumen de: US2025064361A1
An analyte sensor for use in medical devices for measuring analyte data in an analyte carrying fluid, in particular for measuring glucose data, which includes: a first electrode being a working electrode, a second electrode, a substrate carrying the first electrode and the second electrode, at least one membrane which at least partially covers the first electrode, wherein the at least one membrane comprises a membrane material that is impermeable to the analyte carrying fluid and/or the analyte, wherein the at least one membrane comprises at least one opening, and wherein the at least one membrane is configured for controlling the flux of the analyte carrying fluid and/or the analyte to the first electrode via the at least one opening. Methods of operation, a continuous analyte monitoring system and a kit with such a sensor are also disclosed.
Resumen de: US2025064632A1
A fingertip warming device that can be used on either hand, will aid in warming of fingertips to help increase blood flow to the fingertips of the user for the purpose of easing the process of drawing blood, which will be used to check the user's glucose levels. The device will have warming elements either embedded in the distal end of fingertip slots/compartments or allow for the use of a heatable insert that will also reside in the distal end of the device for the purpose of warming the user's fingertips. The device will provide either flaps or a hole through which the user's fingertips can be exposed to allow for collection of a blood sample for testing glucose levels.
Resumen de: US2025070458A1
A glucose monitoring device is provided. The glucose monitoring device includes a housing having a first portion and a second portion, the second portion operable to be placed adjacent to a human body during operation of the glucose monitoring device. The glucose monitoring device further includes a circuit board positioned between the first portion and the second portion of the housing, the circuit board having a trace antenna. The glucose monitoring device further includes a conductive structure spaced apart from the circuit board.
Resumen de: US2025064359A1
Disclosed are devices, systems and methods for in vivo monitoring of localized environment conditions within a patient user by measuring analytes, including glucose, oxygen, and/or other analytes. In some aspects, a sensor device includes a wafer-based substrate, at least one electrochemical sensor two-electrode contingent including a working electrode and a reference electrode on the substrate and configured to detect a target analyte in a body fluid when the sensor device is deployed within a subject's body, where the working electrode is functionalized by a chemical layer configured to facilitate a reaction involving the target analyte that produces an electrical signal; and an electronics unit in communication with the electrochemical sensor electrode contingent to transmit the electrical signal to an external processor.
Resumen de: US2025064353A1
A blood glucose measuring apparatus and a method of operating the blood glucose measuring apparatus are provided. The blood glucose measuring method includes extracting a measurement signal based on signals captured by a cell capsule comprising a reservoir configured to accommodate cells, including distinguishing the signals from noise; and estimating a characteristic of the cells based on the extracted measurement signal. The signals have respective oscillations that are dependent on a membrane action potential bursts phase and a membrane lower potential inter-burst phase of the cells.
Resumen de: WO2025041079A1
The present invention relates to an automatic diabetic foot scanner (1), comprising of, a housing (2), a control unit (3), a communication module (4). The housing (2) accommodates a plurality of modules for detecting a diabetic foot and said plurality of modules are operated by a single on-chip board (18). The plurality of modules include a neuropathy assessment module (5), a blood circulation assessment module (6) and a plantar pressure measurement module (7). Further, the present invention is a cost friendly and portable solution of detecting diabetic foot.
Resumen de: US2025065039A1
The disclosed embodiments are directed to a wearable automatic drug delivery device configured to provide basal-only dosing of insulin. In a primary embodiment, the wearable drug delivery device is configured to provide automatic operation and provides audible alerts and visual status indicators to the patient. In other embodiments, the patient may have some degree of control over the operation of the device by providing tapping gestures on housing of the device. In yet another embodiment, the patient may provide input and receive status from the device via an application executing on a portable computing device in wireless communication with the wearable drug delivery device.
Resumen de: US2025064328A1
The present disclosure includes a handheld processing device including medical applications for minimally and noninvasive glucose measurements. In an embodiment, the device creates a patient specific calibration using a measurement protocol of minimally invasive measurements and noninvasive measurements, eventually creating a patient specific noninvasive glucometer. Additionally, embodiments of the present disclosure provide for the processing device to execute medical applications and non-medical applications.
Resumen de: AU2023341648A1
Systems, devices, and methods for a dual analyte sensor using glucose history from a glucose sensor in combination with data from a ketone sensor to control operation of a user interface device or insulin pump are provided. In some embodiments, the systems, apparatus or methods may make use of combination of glucose history and a β-hydroxybutyrate physiological model to better predict diabetic ketoacidosis (DKA), in comparison to a prediction based on a simple high glucose threshold. In other embodiments, the systems, apparatus or method may include features for generating an estimate of the patient's medication state and/or knowledge of medication information, such as a patient with T1 diabetes mellitus (DM) using an SGLT-2 inhibitor.
Resumen de: EP4512328A2
The present invention relates to a body attachment unit for continuous glucose monitoring. The present invention provides a body attachment unit for continuous glucose monitoring, wherein: the body attachment unit is manufactured in the state in which the body attachment unit is assembled in an applicator, and thus separate additional work is minimized and the body attachment unit can be attached to the body by simply operating the applicator; in particular, a wireless communication chip is disposed in the body attachment unit so as to communicate with an external terminal, and thus simple and convenient use can be achieved without any additional work for connection of a separate transmitter and maintenance and management can also be easily performed; and the monitoring operation is started by a user's manipulation after the body attachment unit is attached to the body, and thus the user can adjust the operation start time to an appropriate point as necessary and the operation can be started in a stabilized state so as to enable more accurate glucose monitoring.
Resumen de: EP4512332A2
An improved sensor set is provided for sensing of a body characteristic, such as glucose. The sensor set includes a mounting base for the sensor and a connector to connect to the mounting base. The connector may contain sensor electronics for wired or wireless communication to an external monitor or display. The mounting base includes a connector fitting adapted to fit into a tubular recess in the connector, wherein the connector fitting includes a key. In some embodiments, the proximal end of the sensor folds around the key such that there are contact pads on both sides of the key. The mounting base and connector include additional features, such as pegs and prongs that allow for unique fitting of compatible mounting bases and connectors, while locking out non-compatible components.
Resumen de: EP4513503A2
The subject matter disclosed herein provides methods for presenting glucose level data. Glucose data for a patient may be received. A current glucose level and a rate of change of the current glucose level may be determined based on the received glucose data. A first interface may be displayed on a screen of a device. The first interface may include a unitary icon. The unitary icon may display the current glucose level and a visualization of the rate of change. Related apparatus, systems, techniques, and articles are also described.
Resumen de: EP4513510A1
This application provides a blood glucose assessment method, an electronic device, and a computer-readable storage medium. The method is applied to a wearable device, and includes: collecting vital sign data of a user in a first cycle of blood glucose assessment; performing blood glucose assessment on the user based on valid vital sign data in the vital sign data, to obtain a blood glucose assessment result corresponding to the first cycle; displaying the blood glucose assessment result corresponding to the first cycle; and automatically starting a next cycle of the blood glucose assessment. According to the technical solutions of this application, blood glucose assessment can be periodically and automatically performed, helping reduce operation complexity for the user.
Resumen de: EP4512326A1
An embodiment may provide a method for calibrating sensitivity for glucose measurement including: obtaining (S1201) an offset value for determining sensitivity; determining (S1203) a first sensitivity from a sensor data and a reference glucose value, based on the offset value; and determining (S1205) sensitivity by adjusting the first sensitivity, wherein the determining (S1205) of the sensitivity includes obtaining one sensitivity, and determining (S1205-1) sensitivity A by adjusting the one sensitivity by reflecting an average sensor data obtained by averaging a plurality of sensor data and an average glucose value obtained by averaging a plurality of glucose values to the one sensitivity; and determining (S1205-2) the sensitivity A as the sensitivity.
Resumen de: EP4512327A1
An embodiment may provide a method for calibrating sensitivity for glucose measurement including: obtaining (S1201) an offset value for determining sensitivity; determining (S1203) a first sensitivity from a sensor data and a reference glucose value, based on the offset value; and determining (S1205) sensitivity by adjusting the first sensitivity, wherein the determining of the sensitivity includes obtaining the first sensitivity, and determining (S1205-1) sensitivity A by adjusting the first sensitivity according to an elapsed period of time after a sensor is inserted into a body; obtaining the first sensitivity, and determining (S1205-1) sensitivity B by adjusting the first sensitivity by reflecting an average sensor data obtained by averaging a plurality of sensor data and an average glucose value obtained by averaging a plurality of glucose values to the first sensitivity; and determining (S1205-2) any one of the sensitivity A and the sensitivity B as the sensitivity.
Resumen de: EP4512325A1
A continuous glucose monitor, comprising a housing and a circuit board arranged in the housing, wherein an electronic component is carried on the circuit board; a probe assembly configured to penetrate skin and connected to the circuit board; and an auxiliary sensor connected to the circuit board and configured to detect a compressed state of the continuous glucose monitor. The continuous glucose monitor provided in the present disclosure can identify its own compressed state, thereby improving the accuracy of glucose measurement.
Resumen de: JP2024137994A
To provide analyte sensors that are responsive to at least two analytes of interest using a single enzyme-based analyte sensor.SOLUTION: Multiple enzymes may be present in one or more active areas of an electrochemical analyte sensor for detecting one or more different analytes. In particular, the analyte sensor may comprise a sensor tail configured for insertion into a tissue and one or more working electrodes having a glucose-responsive active area and an ethanol-responsive active area to detect glucose and ethanol in vivo.SELECTED DRAWING: Figure 9A
Resumen de: AU2023342848A1
Systems, devices and methods are provided for incorporating a medication delivery device into an integrated management system. The integrated management system may be an integrated diabetes management system and may include a glucose monitor, a connected insulin pen, and software. The integrated management system may produce a plurality of reports that may include data related to analyte levels (e.g., glucose levels) and medication delivered (e.g., insulin delivered). The integrated system may also include a mode in which certain types of data are no longer shared and/or stored if the user is not signed into an account. The types of data shared and/or stored when the user is not signed into an account may differ from the types of data shared and/or stored when the user is signed into an account.
Resumen de: US2025062595A1
This disclosure describes a glucose monitor with one or more photonic crystal surface-emitting lasers (PCSELs). The PCSEL comprises a plurality of photonics crystal sections. Each photonics crystal section is operable to emit light of a different wavelength. The horizontal emission by each photonics crystal section may be constrained by edge lattice sections.
Resumen de: US2025058039A1
An infusion system comprising: a device for delivering insulin to a user, the device configured to be mounted the user; a CGM sensor for measuring glucose level in the user and an infusion needle for delivering the insulin to the user; a needle cartridge assembly for supporting the CGM sensor and/or the infusion needle, the needle cartridge assembly configured to move from (1) a telescoping position above the device for delivering insulin, wherein the CGM sensor and/or infusion needle are/is in a retracted position within the device for delivering insulin to (2) an advanced position within the device, wherein the infusion needle and/or CGM sensor are/is in a deployed position inserted into a subcutaneous tissue of the user's skin; and a detachable activation mechanism for (a) moving the needle cartridge assembly from the telescoping position to the advanced position and for (b) releasing the device for delivering insulin upon activation of the detachable activation by the user.
Resumen de: US2025058042A1
The exemplary embodiments may provide a correction factor (CF) for a user that is dynamically adjustable based on current glucose level. In some exemplary embodiments, the CF of the user is adjusted based on the current glucose level of the user. As the current glucose level of the user increases to be above a threshold, the CF may be adjusted to reflect a decrease in the insulin sensitivity of the user. This adjustment may cause the control system to increase the amount of insulin delivered to the user as the glucose level of the user exceeds the threshold. Similarly, the CF of the user may be adjusted based on the current target glucose level of the user or based on a combination of the current glucose level of the user and the current target glucose level of the user.
Resumen de: US2025058041A1
Disclosed herein are techniques related to predicting a physiological condition of a user. In some embodiments, the techniques may involve obtaining one or more glucose concentration values measured from a user; applying, to the one or more glucose concentration values measured from the user, a first glucose prediction model for a first prediction horizon; obtaining, based on applying the first glucose prediction model, a first predicted glucose value of the user; and predicting a second predicted glucose value of the user for a second prediction horizon that is less than the first prediction horizon, based on the first predicted glucose value and at least one glucose concentration value of the one or more glucose concentration values. In some scenarios, the physiological condition may include, for example, hypoglycemia or hyperglycemia.
Resumen de: US2025057448A1
The present invention relates to a device (12) for determining a state of health of a patient (11), comprising: an input interface (16) for receiving a glucose measurement value with information relating to a glucose level of the patient and a glucose uptake input value with information relating to a glucose uptake of the patient; an estimation unit (18) for determining the state of health of the patient on the basis of the received values and a predefined state model, which represents the state of health of the patient by means of a state vector and using a plurality of model parameters, wherein the state vector comprises a glucose model value with information relating to the glucose level of the patient and can comprise an insulin model value with information relating to the insulin level of the patient; a comparison unit (20) for determining a deviation between the glucose measurement value and the glucose model value; and an individualization unit (22) for the patient-specific update of a model parameter on the basis of the determined deviation. Further model parameters can comprise individual glucose or insulin sensitivities, the incretin sensitivity and sensitivities with respect to lifestyle input values. The present invention also relates to a system (10) and to a method for determining a state of health of a patient (11).
Nº publicación: WO2025037363A1 20/02/2025
Solicitante:
NIPPON TELEGRAPH AND TELEPHONE CORP [JP]
\u65E5\u672C\u96FB\u4FE1\u96FB\u8A71\u682A\u5F0F\u4F1A\u793E
Resumen de: WO2025037363A1
A skin phantom (1) is obtained by laminating a porous film (3) on a hydrogel (2) comprising a gelling agent, glucose, an electrolyte, and water. The porous film (3) is one that is impregnated with a hydrophobic material or one in which a hydrophobic material is formed on the surface of the porous film (3) on the side in contact with the hydrogel (2).
BOPI
Sede Electrónica
